A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2026-05-29
• Target enrollment: 0
• Participant gender: All

Summary

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborator: Translational Research in Oncology

Criteria

Inclusion Criteria:

• Patient is ≥ 18 years-old at the time of PICF signature

• Patient is female with known menopausal status at the time of randomization or initiation of adjuvant ET (whichever occurs earlier), or male.

• Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization.

• Patient has breast cancer that is positive for ER and/or PgR

• Patient has HER2-negative breast cancer

• Patient has available archival tumor tissue from the surgical specimen

• Patient after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories: anatomic stage group II or III

• If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines

• If indicated, patient has completed adjuvant radiotherapy according to the institutional guidelines

• Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• Patient has no contraindication for the adjuvant ET in the trial and is planned to be treated with ET for 5 years

Exclusion Criteria:

• Patient has received any CDK4/6 inhibitor

• Patient has received prior treatment with tamoxifen, raloxifene or AIs for reduction in risk ("chemoprevention") of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. Patient is concurrently using hormone replacement therapy.

• Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin.

• Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET

• Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.

• Patient is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET

• Patient has had major surgery, chemotherapy or radiotherapy within 14 days prior to randomization

• Patient has not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies

• Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization

• Patient has known HIV infection, Hepatitis B or C infection

• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality

• Patient is currently receiving any of the following substances within 7 days before randomization - Concomitant medications, herbal supplements, and/or fruits that are known as strong inhibitors or inducers of CYP3A4/5 or Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5

• is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting trial treatment

• Patient has impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments

• Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol

• Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s) (whichever is longer), or participation in any other type of medical research judged not to be scientifically or medically compatible with this trial.

• Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial